Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
Clinical-stage biopharmaceutical company developing GPCR-targeting monoclonal antibodies for cardiovascular, metabolic, and oncology diseases.
Gmax Biopharm is a clinical-stage biopharmaceutical company based in Hangzhou, China, that develops monoclonal antibodies and M-Body therapeutics targeting G-protein coupled receptors (GPCRs) to treat unmet medical needs. The organization maintains a robust pipeline that currently includes six clinical development programs, two investigational new drug (IND) filing programs, and over ten preclinical studies. Its primary therapeutic focus areas encompass cardiovascular diseases, metabolic disorders, and oncology, with specific drug candidates targeting type 2 diabetes, obesity, and pulmonary arterial hypertension. The company's research and development leadership team draws on decades of prior industry experience from major pharmaceutical corporations, including Amgen, Bristol-Myers Squibb, and Genentech. To support its advancing clinical pipeline and future commercialization efforts, the enterprise operates a dedicated manufacturing facility located in Zhengzhou, China. Gmax Biopharm was founded in 2010 by Shuqian Jing and Richard Xu.
Gmax Biopharm has raised $78.0M across 1 funding round.
Gmax Biopharm has raised $78.0M in total across 1 funding round.
Gmax Biopharm has raised $78.0M across 1 funding round. Most recently, it raised $78.0M Series C in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 9, 2021 | $78M Series C | China Merchants Group | — | Announced |
Gmax Biopharm has raised $78.0M in total across 1 funding round.
Gmax Biopharm's investors include China Merchants Group.